• Profile

Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials

JAMA Dec 08, 2019

Wessels AM, Tariot PN, Zimmer JA, et al. - Researchers examined how lanabecestat affects the progression of early Alzheimer disease (AD) and mild AD dementia. Two global randomized clinical trials (AMARANTH, n = 2,218; DAYBREAK-ALZ, n = 1,722) were undertaken at 257 and 251 centers and located in 15 and 18 countries or territories, respectively. Patients were randomized to receive (1:1:1) once-daily oral doses of lanabecestat 20 mg, lanabecestat 50 mg, or placebo. Outcomes revealed that in patients with early AD or mild AD dementia, lanabecestat was generally well tolerated but had no higher efficacy at both doses tested (20 mg and 50 mg) in slowing cognitive or functional decline compared with placebo.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen